Arcellx Q2 2021 Earnings Report
Key Takeaways
Arcellx reported its Q2 2022 financial results, highlighting the completion of an upsized follow-on offering, presentation of CART-ddBCMA Phase 1 expansion trial data, and preclinical results from CART-ddBCMA published in Molecular Cancer Therapeutics.
Completed an upsized follow-on offering of common stock, raising $128.8 million in gross proceeds.
Presented robust long-term responses from its CART-ddBCMA Phase 1 expansion trial at the 2022 ASCO Annual Meeting.
Preclinical results from CART-ddBCMA were published in Molecular Cancer Therapeutics.
First patient dosed in ACLX-001, a Phase 1 study utilizing Arc-SparX technology.
Arcellx
Arcellx
Forward Guidance
Arcellx looks forward to presenting at ESMO, initiating the Phase 2 pivotal CART-ddBCMA trial, presenting longer-term patient data from the Phase 1 CART-ddBCMA expansion trial, and initiating the Phase 1 ARC-SparX clinical trial of ACLX-002.
Positive Outlook
- Presenting an encore presentation of CART-ddBCMA Phase 1 study at ESMO.
- Initiating Phase 2 pivotal CART-ddBCMA (iMMagine) trial in patients with r/r MM.
- Presenting longer-term patient data from Phase 1 CART-ddBCMA expansion trial in r/r MM.
- Initiating Phase 1 ARC-SparX clinical trial of ACLX-002 in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Scaling the business and advancing the novel platform to help as many patients as possible.
Challenges Ahead
- Risks associated with the timing and outcomes of clinical trials.
- Uncertainties regarding the potential impact of product candidates and platforms.
- Risks related to the timing of achievement of milestones.
- Risks associated with the ability to fund operations.
- Risks and uncertainties that may be found in the company's filings with the SEC.